| Sam Blankson-hemans, MD | |
|
600 N Wolfe St, Baltimore, MD 21287-0005 | |
| (410) 955-5000 | |
| Not Available |
| Full Name | Sam Blankson-hemans |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 23 Years |
| Location | 600 N Wolfe St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215915749 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | D0062601 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doctors' Community Hospital | Lanham, MD | Hospital |
| Anne Arundel Medical Center | Annapolis, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Company Llc | 4587559026 | 192 |
| Anesthesia Company Llc | 4587559026 | 192 |
News Archive
Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.
Concerns raised by scientists in the U.S. last month about Bisphenol A, a controversial chemical found in most plastic baby bottles has led to calls from groups in Britain for all baby bottles to be clearly labelled.
The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule.
PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, today announced that it has been certified by Surescripts to receive controlled and non-controlled substance prescription orders electronically.
A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.
› Verified 2 days ago
| Entity Name | North American Partners In Anesthesia (virginia), Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922031442 PECOS PAC ID: 9931192739 Enrollment ID: O20040407000294 |
News Archive
Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.
Concerns raised by scientists in the U.S. last month about Bisphenol A, a controversial chemical found in most plastic baby bottles has led to calls from groups in Britain for all baby bottles to be clearly labelled.
The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule.
PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, today announced that it has been certified by Surescripts to receive controlled and non-controlled substance prescription orders electronically.
A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.
› Verified 2 days ago
| Entity Name | First Colonies Anesthesia Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740218767 PECOS PAC ID: 8426039744 Enrollment ID: O20040607001456 |
News Archive
Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.
Concerns raised by scientists in the U.S. last month about Bisphenol A, a controversial chemical found in most plastic baby bottles has led to calls from groups in Britain for all baby bottles to be clearly labelled.
The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule.
PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, today announced that it has been certified by Surescripts to receive controlled and non-controlled substance prescription orders electronically.
A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.
› Verified 2 days ago
| Entity Name | North American Partners In Anesthesia Maryland Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093707879 PECOS PAC ID: 1850283144 Enrollment ID: O20140317000783 |
News Archive
Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.
Concerns raised by scientists in the U.S. last month about Bisphenol A, a controversial chemical found in most plastic baby bottles has led to calls from groups in Britain for all baby bottles to be clearly labelled.
The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule.
PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, today announced that it has been certified by Surescripts to receive controlled and non-controlled substance prescription orders electronically.
A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.
› Verified 2 days ago
| Entity Name | Anesthesia Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871548156 PECOS PAC ID: 4587559026 Enrollment ID: O20180522001908 |
News Archive
Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.
Concerns raised by scientists in the U.S. last month about Bisphenol A, a controversial chemical found in most plastic baby bottles has led to calls from groups in Britain for all baby bottles to be clearly labelled.
The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule.
PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, today announced that it has been certified by Surescripts to receive controlled and non-controlled substance prescription orders electronically.
A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.
› Verified 2 days ago
| Entity Name | Sandman Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578030193 PECOS PAC ID: 7416292339 Enrollment ID: O20181221000739 |
News Archive
Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.
Concerns raised by scientists in the U.S. last month about Bisphenol A, a controversial chemical found in most plastic baby bottles has led to calls from groups in Britain for all baby bottles to be clearly labelled.
The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule.
PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, today announced that it has been certified by Surescripts to receive controlled and non-controlled substance prescription orders electronically.
A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sam Blankson-hemans, MD 9910 Franklin Square Dr, 2110, Baltimore, MD 21236-4902 Ph: (410) 933-6423 | Sam Blankson-hemans, MD 600 N Wolfe St, Baltimore, MD 21287-0005 Ph: (410) 955-5000 |
News Archive
Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.
Concerns raised by scientists in the U.S. last month about Bisphenol A, a controversial chemical found in most plastic baby bottles has led to calls from groups in Britain for all baby bottles to be clearly labelled.
The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule.
PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, today announced that it has been certified by Surescripts to receive controlled and non-controlled substance prescription orders electronically.
A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.
› Verified 2 days ago
Kathryn Rosenblatt, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1800 Orleans St, Baltimore, MD 21287 Phone: 410-955-7461 Fax: 410-614-7903 | |
Dr. Tiffani Danielle Pittman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5601 Loch Raven Blvd, Baltimore, MD 21239 Phone: 443-444-4863 Fax: 443-444-4997 | |
Aaron Sachs, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 22 S Greene St # S11c, University Of Maryland Department Of Anesthesia, Baltimore, MD 21201 Phone: 410-328-1239 | |
Dr. Mohamed Ehab Ramadan Mohamed Ramadan, MBBCH, MSC, PHD Anesthesiology Medicare: Medicare Enrolled Practice Location: 600 North Wolfe Street, Nelson 2-131, Baltimore, MD 21287 Phone: 410-955-1818 | |
Lynette Mark, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-6353 | |
Charles Lin, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 900 Canton Ave, Baltimore, MD 21229 Phone: 410-368-3045 Fax: 410-951-4009 | |
Dr. Jasjit B Atwal, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 110 S Paca St, Suite 300 6th Fl, Baltimore, MD 21201 Phone: 410-328-6720 Fax: 410-328-1674 |